[go: up one dir, main page]

MA33241B1 - Composes pour le traitement de troubles metaboliques - Google Patents

Composes pour le traitement de troubles metaboliques

Info

Publication number
MA33241B1
MA33241B1 MA34245A MA34245A MA33241B1 MA 33241 B1 MA33241 B1 MA 33241B1 MA 34245 A MA34245 A MA 34245A MA 34245 A MA34245 A MA 34245A MA 33241 B1 MA33241 B1 MA 33241B1
Authority
MA
Morocco
Prior art keywords
metabolic disorders
compounds
treatment
diabetes
exhibit
Prior art date
Application number
MA34245A
Other languages
Arabic (ar)
English (en)
Inventor
Oscar Barba
Tom Banksia Dupree
Matthew Colin Thor Fyfe
Revathy Perpetua Jeevaratnam
Karen Lesley Schofield
Thomas Staroske
Alan John William Stewart
Simon Andrew Swain
David Matthew Withall
Peter Timothy Fry
Thomas Martin Krulle
David French Stonehouse
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of MA33241B1 publication Critical patent/MA33241B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés thérapeutiques qui présentent une activité d'agonistes de GPR119 et sont utiles pour traiter des troubles métaboliques, y compris le diabète de type 2.
MA34245A 2009-03-12 2010-03-12 Composes pour le traitement de troubles metaboliques MA33241B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0904285.4A GB0904285D0 (en) 2009-03-12 2009-03-12 Compounds for the treatment of metabolic disorders
PCT/GB2010/050441 WO2010103334A1 (fr) 2009-03-12 2010-03-12 Composés pour le traitement de troubles métaboliques

Publications (1)

Publication Number Publication Date
MA33241B1 true MA33241B1 (fr) 2012-05-02

Family

ID=40600947

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34245A MA33241B1 (fr) 2009-03-12 2010-03-12 Composes pour le traitement de troubles metaboliques

Country Status (18)

Country Link
US (1) US20120059014A1 (fr)
EP (1) EP2406251A1 (fr)
JP (1) JP2012520283A (fr)
KR (1) KR20110133045A (fr)
CN (1) CN102395578A (fr)
AU (1) AU2010222672A1 (fr)
BR (1) BRPI1009783A2 (fr)
CA (1) CA2754791A1 (fr)
CL (1) CL2011002182A1 (fr)
EA (1) EA201190207A1 (fr)
GB (1) GB0904285D0 (fr)
IL (1) IL215050A0 (fr)
MA (1) MA33241B1 (fr)
MX (1) MX2011009493A (fr)
PE (1) PE20120218A1 (fr)
SG (1) SG174363A1 (fr)
WO (1) WO2010103334A1 (fr)
ZA (1) ZA201107449B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007007751A1 (de) * 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
WO2010149685A1 (fr) 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh Nouveaux composés, composition pharmaceutique et procédés s'y rapportant
EA201200046A1 (ru) 2009-06-24 2012-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения, фармацевтическая композиция и связанные с ними способы
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
GB201006167D0 (en) * 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012066077A1 (fr) 2010-11-18 2012-05-24 Prosidion Limited Dérivés 1,4 di substitués pyrolidine-3-yl-amine et leur utilisation pour le traitement de troubles métaboliques
SMT201700035T1 (it) 2011-05-13 2017-03-08 Array Biopharma Inc Composti di pirrolidinil urea, pirrolidinil tiourea e pirrolidinil guanidina come inibitori di chinasi trka
CN103958495B (zh) 2011-06-09 2018-06-22 理森制药股份公司 作为gpr-119的调节剂的化合物
GB2497351A (en) * 2011-12-09 2013-06-12 Prosidion Ltd Compounds useful as GPR119 agonists
JP2015522080A (ja) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
WO2016131198A1 (fr) * 2015-02-18 2016-08-25 Eli Lilly And Company Composés pyrazole
WO2017161028A1 (fr) * 2016-03-16 2017-09-21 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
WO2000012705A2 (fr) 1998-09-01 2000-03-09 Basf Aktiengesellschaft Methodes permettant d'ameliorer la fonction des recepteurs heterologues couples a la proteine g
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP4958560B2 (ja) 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
JP5065908B2 (ja) 2004-12-24 2012-11-07 プロシディオン・リミテッド Ｇタンパク質結合受容体作動薬
EP1838311A1 (fr) 2004-12-24 2007-10-03 Prosidion Limited Agonistes du récepteur couplé aux protéines g (gpr116) et leur emploi dans le traitement de l'obésité et du diabète
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
JP2008545010A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇタンパク質共役受容体アゴニスト
BRPI0613505A2 (pt) 2005-06-30 2011-01-11 Prosidion Ltd agonistas de gpcr
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
BRPI0710839A2 (pt) 2006-04-06 2011-08-23 Prosidion Ltd agonistas heterocìclicos de gpcr
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
WO2007148185A2 (fr) 2006-06-21 2007-12-27 Pfizer Products Inc. 3-amino-pyrrolidino-4-lactames substitués
MY157365A (en) 2006-12-06 2016-05-31 Smithkline Beecham Corp Chemical compounds and uses
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
AR064735A1 (es) * 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
WO2008081208A1 (fr) 2007-01-04 2008-07-10 Prosidion Limited Agonistes de gpcr pipéridiniques
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2009014910A2 (fr) 2007-07-19 2009-01-29 Metabolex, Inc. Agonistes de recepteurs heterocycliques a liaison n utilises dans le traitement du diabete et des troubles metaboliques
WO2009034388A1 (fr) 2007-09-10 2009-03-19 Prosidion Limited Composés pour le traitement de troubles métaboliques
KR101136774B1 (ko) 2007-10-18 2012-04-19 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 금속 피복 폴리이미드 복합체 및 그 복합체의 제조 방법 그리고 전자 회로 기판의 제조 방법
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
CN101621337B (zh) 2008-06-30 2013-08-07 华为技术有限公司 一种时延调节装置与方法
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
EP2321308B9 (fr) 2008-07-10 2012-08-08 Prosidion Limited Agonistes des récepteurs couplés aux protéines g (gpcr) piperidines
CN102083813A (zh) 2008-07-10 2011-06-01 普洛希典有限公司 哌啶基gpcr激动剂
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds

Also Published As

Publication number Publication date
SG174363A1 (en) 2011-10-28
EA201190207A1 (ru) 2012-04-30
CA2754791A1 (fr) 2010-09-16
EP2406251A1 (fr) 2012-01-18
ZA201107449B (en) 2012-06-27
IL215050A0 (en) 2011-11-30
PE20120218A1 (es) 2012-03-19
WO2010103334A1 (fr) 2010-09-16
GB0904285D0 (en) 2009-04-22
AU2010222672A1 (en) 2011-11-03
JP2012520283A (ja) 2012-09-06
CN102395578A (zh) 2012-03-28
US20120059014A1 (en) 2012-03-08
BRPI1009783A2 (pt) 2016-03-08
CL2011002182A1 (es) 2012-03-30
MX2011009493A (es) 2011-10-11
KR20110133045A (ko) 2011-12-09

Similar Documents

Publication Publication Date Title
MA33241B1 (fr) Composes pour le traitement de troubles metaboliques
MA33190B1 (fr) Composes pour le traitement de troubles metaboliques
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
TW200612926A (en) Compounds and compositions as ppar modulators
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
SG170813A1 (en) New compounds
EP2111107A4 (fr) Agonistes de récepteur hétérocyclique pour le traitement du diabète et de troubles métaboliques
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
IN2012DN02471A (fr)
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200900831A1 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов
TW200602330A (en) Compounds and compositions as PPAR modulators
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
TW200600505A (en) Compounds and compositions as ppar modulators
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.